News & Events

Disc Medicine to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass. (May 21, 2021) – Disc Medicine, a company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc Medicine, will

More News

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

IND accepted for phase 2 clinical trial in DBA patients; study is expected to initiate mid-year 2023 WATERTOWN, Mass., March 21, 2023...

read more

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

WATERTOWN, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) — Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

read more

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

WATERTOWN, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development...

read more